Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy

European Journal of Cancer

Volumn 46, Issue 8, 2010, Pages 1359-1364

  Han, Liz Y ^a   Karavasilis, Vasilios ^b   Hagen, Tom van ^c   Nicum, Shibani ^d   Thomas, Karen ^e   Harrison, Michelle ^f   Papadopoulos, Panagiotis ^g   Blake, Peter ^a   Barton, Desmond P J ^a   Gore, Martin ^a   Kaye, Stan B ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b PAPAGEORGIOU GENERAL HOSPITAL   (Greece)

^c ROYAL PERTH HOSPITAL   (Australia)

^d CHURCHILL HOSPITAL   (United Kingdom)

^e ROYAL MARSDEN HOSPITAL   (United Kingdom)

^f ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^g UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

CA125; Doubling time; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; PLATINUM COMPLEX; TAXANE DERIVATIVE;

ADULT; AGE; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER RELAPSE; CANCER SURVIVAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SURVIVAL RATE; ANALYSIS OF VARIANCE; BLOOD; DISEASE COURSE; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; TIME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-125 ANTIGEN; DISEASE PROGRESSION; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TIME FACTORS;

EID: 77951673839     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.02.012     Document Type: Article

References (20)

1. Parkin D.M., Bray F., Ferlay J., et al. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
2. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2009. CA Cancer J Clin 59 (2009) 225-249
3. Partridge E.E., and Barnes M.N. Epithelial ovarian cancer: prevention, diagnosis, and treatment. CA Cancer J Clin 49 (1999) 297-320
4. Ozols R.F. Treatment goals in ovarian cancer. Int J Gynecol Cancer 15 Suppl. 1 (2005) 3-11
5. van der Burg M.E., Lammes F.B., and Verweij J. The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer. Ann Oncol 1 (1990) 301-302
6. Crawford S.M., and Peace J. Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary?. Ann Oncol 16 (2005) 47-50
7. Krebs H.B., Goplerud D.R., Kilpatrick S.J., et al. Role of Ca 125 as tumor marker in ovarian carcinoma. Obstet Gynecol 67 (1986) 473-477
8. Rustin G.J., Nelstrop A.E., Tuxen M.K., et al. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann Oncol 7 (1996) 361-364
9. Rustin G.J., Marples M., Nelstrop A.E., et al. Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol 19 (2001) 4054-4057
10. Rustin G.J., and van der Burg M.E. A randomized trial of ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials). J Clin Oncol (2009) 27
11. Rocconi R.P., Matthews K.S., Kemper M.K., et al. The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer. Gynecol Oncol 114 (2009) 242-245
12. Zorn K.K., Tian C., McGuire W.P., et al. The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group study. Cancer 115 (2009) 1028-1035
13. Juretzka M.M., Barakat R.R., Chi D.S., et al. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy. Gynecol Oncol 104 (2007) 176-180
14. Han L.Y., Landen Jr. C.N., Kamat A.A., et al. Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma. J Clin Oncol 24 (2006) 755-761
15. Chi D.S., Venkatraman E.S., Masson V., et al. The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol Oncol 77 (2000) 227-231
16. Berek J.S., Taylor P.T., and Nicodemus C.F. CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer. J Immunother 31 (2008) 207-214
17. Klotz L. Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer. Eur Urol 47 (2005) 16-21
18. Schmid H.P., McNeal J.E., and Stamey T.A. Clinical observations on the doubling time of prostate cancer. Eur Urol 23 Suppl. 2 (1993) 60-63
19. Yap T.A., Carden C.P., and Kaye S.B. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 9 (2009) 167-181
20. Society of Gynecologic Oncologists. Statement on Use of CA125 for Monitoring Ovarian Cancer; June 2009. .